Episode: 6 - Fireside Chat: Innovation and Investment in Biomanufacturing of Future Medicine

At the most recent Bioprocessing Summit, David Y. H. Chang, CEO of Taiwan Bio-Manufacturing Company; Bo Wiinberg, Chief Business Development Officer of Novo Nordisk Foundation Cellerator; and Paul Lewus, Vice President of Site Operations at Amgen gathered for a fireside chat moderated by Ran Zheng, former CEO of Landmark Bio, to discuss the technologies and innovations shaping the future of biomanufacturing. The conversation explored upcoming trends, investment opportunities, and modalities into the next decade, as well as the question: how should the industry best prepare for all of it? Links from this episode:  Bioprocessing Summit Landmark Bio Novo Nordisk Foundation Cellerator Taiwan Bio-Manufacturing Company (TBMC) Amgen  Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.